David Woodley is a Dermatology physician affiliated with University of Southern California. OpenAlex indexes 13 publications with 1,125 citations (h-index 13); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- MSC EVs in Dystrophic Epidermolysis Bullosa
Sponsor: Aegle Therapeutics
- Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Sponsor: University of Southern California
- Gentamicin for RDEB
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
28.9%Corticosteroid28.9%Triamcinolone Acetonide100%Part D≥27 patientsSensory organs
21.1%Corticosteroid21.1%Clobetasol Propionate73%Hydrocortisone27%Part D<11 patientsMetabolism & gastrointestinal
21.1%Corticosteroid21.1%Prednisone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 1989–2022 per NIH RePORTER. The latest:
- The Role of Exogenous Type VII Collagen on the Healing of Skin Wounds
Va Greater Los Angeles Healthcare System
FY2022I01BX002028 - The Role of Exogenous Type VII Collagen on the Healing of Skin Wounds
Va Greater Los Angeles Healthcare System
FY2021I01BX002028 - The Role of Exogenous Type VII Collagen on the Healing of Skin Wounds
Va Greater Los Angeles Healthcare System
FY2020I01BX002028
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Rohit Varma, MD
University of Southern California
John Ringman, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”